EGb761
PreclinicalSmall molecule
IpsenEGb761 is one of 10 small molecule programs targeting Cognitive Disorder. It is currently in Preclinical.
1
Indications
3
Total Trials
0
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Cognitive Disorder
#DrugCompanyPhaseTrials
1Victoza
Novo NordiskApproved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Biological Check-up
UUniversity Hospital, Bordeaux
Phase 2
Lithium Treatment
VVA Office of Research and Development
Phase 2
Methylthioninium Chloride
PProvepharm SAS
Preclinical
Bupivacaine Liposome
Pacira Pharmaceuticals, IncPreclinical
Antihypertensive Agents
NNational Heart, Lung, and Blood Institute (NHLBI)
Preclinical
Intranasal Insulin
UUniversity Health Network, Toronto
Preclinical
EGb761
IpsenPreclinical
Divaza
MMateria Medica Holding
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for EGb761. EMBL-EBI & Wellcome Sanger Institute.
- [4]